Fact CheckerSign in

NCT07245576Recruiting

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

A Study to Evaluate the Accuracy of Primary Care Diagnosis Using Oscillometry and Fractional Exhaled Nitric Oxide for Asthma and COPD Versus Specialist Diagnosis in Patients With Suspected Asthma or COPD

Source: ClinicalTrials.gov · Last updated 13 Oct 2026

Brief summary (registry, in English)

Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry. While spirometry is a foundational tool, its diagnostic accuracy is often limited by the patient's ability to perform forceful breathing maneuvers, as well as technical and reproducibility challenges, and the need for proper equipment and training. These constraints can compromise effective diagnosis of asthma and COPD in primary care settings. Prompt and accurate diagnosis by primary care physicians is essential for better patient outcomes. Although variable airflow limitation often measured as a change in FEV1 after bronchodilator is a hallmark of asthma, inconsistencies in test quality and reversibility criteria create challenges in distinguishing asthma from COPD. These complexities highlight the need for alternative diagnostic tools beyond traditional spirometry. This observational study is designed to evaluate the diagnostic accuracy and technical feasibility of using oscillometry and FeNO testing in primary care for suspected asthma and COPD, compared to conventional specialist-based diagnostics. The study will be conducted across 7 countries in the MEA, Asia, and Latin America, with two hospital sites per country. Primary care physicians will be trained in oscillometry and FeNO testing using standardized protocols and tools such as the Ambulatory Lung Diagnosis System following GINA and GOLD guidelines. Eligible patients will provide consent, complete a history and symptom questionnaire, and undergo primary care-based assessment for a provisional diagnosis. If specialist assessment cannot occur the same day, it will be done within three days. No follow-up visits are planned. Study outcomes will inform the feasibility and accuracy of integrating these methods into routine care, aiming to improve the early and reliable diagnosis of asthma and COPD.

Status (registry)
Recruiting
Study type
Observational
Enrollment
600 (estimated)
First submitted
6 Oct 2025
Start date
26 Dec 2025
Primary completion date
30 Apr 2027
Lead sponsor
AstraZeneca
Diseases
Asthma, COPD
NCT number
NCT07245576

What you commit to

  • Study type: Observational
  • Planned participants: 600
  • From 26 Dec 2025 to the primary completion date, 30 Apr 2027
  • 12 sites in 7 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior diagnosis of COPD or asthma.
  • Use of ICS in the last 6 months or use of oral corticosteroids in the last 3 months.

Other illness

  • Any diseases that influence lung function result such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, and interstitial lung disease.
  • Any history of recent surgery that affects lung function results, including but not limited to thoracotomy surgery, pneumothorax surgery, and thoracic drainage.
  • Contraindication to spirometry or oscillometry test, or allergy to bronchodilator.

Other

  • Patients are excluded from the study if any of the following criteria apply:
  • Currently pregnant or breast-feeding women.
  • If the investigator judges that the patient is unlikely to comply with study procedures, restrictions, and requirements.

Who the study is looking for

  • Patients are eligible to be included in the study if all the following criteria apply and after providing written informed consent:
  • Suspected asthma (asthma group)
  • Patients ≥ 18 years old or with legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the ICF.
  • Patients presenting with symptoms of wheezing, cough, chest tightness, shortness of breath, but without a clinically confirmed diagnosis of asthma.
    • Suspected COPD (COPD group)
  • Patients ≥ 40 years old at the time of signing the ICF.
  • Patients presenting with symptoms of dyspnea, chronic cough or sputum production, but without a clinically confirmed diagnosis of COPD.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (12)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
-
Coordinator of this site? Confirm its status
DubaiUnited Arab EmiratesNot yet recruiting
-
Coordinator of this site? Confirm its status
Buenos AiresArgentinaRecruiting
-
Coordinator of this site? Confirm its status
MedozaArgentinaRecruiting
-
Coordinator of this site? Confirm its status
AlexandriaEgyptNot yet recruiting
-
Coordinator of this site? Confirm its status
El WailiEgyptNot yet recruiting
-
Coordinator of this site? Confirm its status
MonterreyMexicoNot yet recruiting
-
Coordinator of this site? Confirm its status
Santiago de Quer TaroMexicoNot yet recruiting
-
Coordinator of this site? Confirm its status
RiyadhSaudi ArabiaNot yet recruiting
-
Coordinator of this site? Confirm its status
TaichungTaiwanNot yet recruiting
-
Coordinator of this site? Confirm its status
Taoyuan CityTaiwanNot yet recruiting
-
Coordinator of this site? Confirm its status
HanoiVietnamNot yet recruiting
-
Coordinator of this site? Confirm its status
Ho Chi Minh CityVietnamRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.